The manipulation of transmembrane signaling by G protein-coupled receptors (GPCRs) constitutes perhaps the single most important therapeutic target in medicine. Therapeutics acting on GPCRs have traditionally been classified as agonists, partial agonists, or antagonists based on a two state model of receptor function embodied in the ternary complex model. Over the past decade, however, many lines of investigation have shown that GPCR signaling exhibits greater diversity and 'texture' than previously appreciated. Signal diversity arises from numerous factors, among them the ability of receptors to adopt multiple 'active' states with different effector coupling profiles, the formation of receptor dimers that exhibit unique pharmacology, signaling, and trafficking, the dissociation of receptor 'activation' from desensitization and internalization, and the discovery that non-G protein effectors mediate some aspects of GPCR signaling. At the same time, clustering of GPCRs with their downstream effectors in membrane microdomains, and interactions between receptors and a plethora of multidomain scaffolding proteins and accessory/chaperone molecules confers signal preorganization, efficiency, and specificity. More importantly it is likely that alteration in the interactions of these proteins with GPCRs may occur in aging or neurodegenerative disorders, thus defining a distinct 'pharmacology' from that seen in young organisms or normal physiology. In this context, the concept of agonist selective trafficking of receptor signaling, which recognizes that a bound ligand may select between a menu of 'active' receptor conformations and induce only a subset of the possible response profile, presents the opportunity to develop drugs that change the quality as well as the quantity of efficacy and enhance these qualities for specific disorders or other paradigms. As a more comprehensive understanding of the complexity of GPCR signaling is developed, the rational design of ligands possessing increased specific efficacy and attenuated side effects may become the standard mode of drug development.
INTRODUCTION
The heptahelical G protein-coupled receptors (GPCRs) constitute the most diverse form of transmembrane signaling protein. Approximately 1% of the mammalian genome encodes GPCRs, and about 450 of the approximately 950 predicted human GPCRs are expected to be receptors for endogenous ligands [1] [2] . GPCRs detect an extraordinarily diverse set of stimuli in the external environment, from photons of light and ions to small molecule neurotransmitters, peptides, glycoproteins, and phospholipids. Emphasizing their importance as therapeutic targets, nearly 40% of all current drugs target GPCRs for their actions [3] .
The mechanism by which GPCRs transduce extracellular messages into intracellular cellular responses has long been envisioned as a simple linear model in which agonist binding promotes transition of the receptor from an 'off' to an 'on' state capable of engaging heterotrimeric guanine nucleotidebinding (G) proteins, whose dissociated G and G subunits in turn activate or inhibit various downstream effector molecules. Implicit in this model is the concept that a *Address correspondence to this author at the Laboratory of Neurosciences & MedStar Research Institute, National Institute on Aging Intramural Research Program, Gerontology Research Center, 5600 Nathan Shock Drive, Johns Hopkins Medical Center, Baltimore, MD 21224, USA; Tel: 410 558 8472; Fax: 410 558 8323; E-mail: maudsleyst@grc.nia.nih.gov GPCR agonist will impact every consequence of receptor activation in the same fashion, whether G protein coupling, receptor desensitization, internalization or trafficking. Unfortunately this simple model has been overshadowed by experimental evidence documenting the existence of multiple 'active' receptor states, alternative mechanisms of signaling, and preogranization of GPCR signaling units. These findings have dramatically expanded our notions of the complexity and 'texture' of GPCR signaling and forced a re-examination of the fundamental concepts of agonism and antagonism. It is increasingly clear that for a given GPCR, the optimal receptor conformation for G protein activation differs between G protein pools, and that synthetic, and in some cases naturally-occurring, ligands can selectively promote different coupling conformations of the receptor (for examples see below). Many examples now exist of 'agonists' that activate only a subset of potential G protein partners or induce G protein coupling without triggering desensitization and endocytosis, or of 'antagonists' that cause receptor desensitization or that initiate apparently G protein-independent signals without producing detectable activation of heterotrimeric G proteins. Here, we examine current insights into the source of GPCR signaling diversity and specificity, and discuss the impact of these factors on the classical concepts of agonism and the process of drug discovery for neurological disorders.
THE EVOLUTION OF RECEPTOR THEORY The Ternary Complex Model of GPCR Function
Ligand-mediated GPCR activation induces guanine nucleotide exchange at heterotrimeric G proteins. The ligand, upon binding, activates the receptor by causing conformational shifts within the heptahelical transmembrane domain bundle that are transmitted to the intracellular transmembrane loops and carboxyl terminus. These conformational changes alter the ability of the receptor to interact with intracellular G proteins and catalyze the exchange of GDP for GTP on the heterotrimeric G protein alpha subunit. The GTP-bound alpha subunit stimulates its cognate downstream effectors, e.g. an adenylyl cyclase or phospholipase C (PLC), conveying information about the presence of an extracellular stimulus to the intracellular environment.
When considered in the simplest way, a GPCR can act as a switch, existing in either an empty "off" state or an agonist-bound "on" state. Such early allosteric models of membrane receptor function were introduced in the late 1960s [4] . Even before the cloning of GPCRs it was shown that hormonal stimulation of adenylyl cyclase was specifically controlled by additional factors, i.e. guanine nucleotides [5] . The importance of these signaling factors in mediating receptor activation was reinforced with the finding that -adrenergic receptors exhibit two affinity states for agonists and that the relative proportions of each state were modulated by the presence of guanine nucleotides [6] . This model advanced to explain these phenomena predicted that in the presence of GDP, agonist binding promotes the formation of a long-lived ternary complex between agonist (H), GPCR (R), and heterotrimeric G protein (G) that exhibits high agonist binding affinity. In the absence of the G protein, or when the presence of GTP allows for receptor-catalyzed G protein activation, the H-R-G complex is dissociated and the receptor resides in a low affinity (H-R) state.
The Extended Ternary Complex Model
The creation of chimeric receptors led to the demonstration that 1b adrenergic receptors with relatively conservative substitutions of 2 adrenergic receptor amino acid sequences in the C-terminal portion of the third intracellular loop could activate Gq/11 proteins in the absence of agonist [7] . In the limit case it was shown that mutation of a single residue, Ala293, of the 1b-adrenergic receptor to any other amino acid increased the agonist affinity of the receptor and produced constitutive stimulation of phosphatidylinositol hydrolysis [8] . Using analogous constitutively active mutants of the 2-adrenergic receptor, it was demonstrated that some ligands that appear to be classical competitive antagonists on native receptors show selective high affinity for the inactive receptor and suppress basal receptor activity [9] . Ligands possessing these properties have been termed "negative antagonists" or "inverse agonists". This, and subsequent work involving a large number of GPCRs, led to the proposal that receptors exist in spontaneous equilibrium between two conformations (active: R*; inactive: R) that differ in their ability to activate G proteins [10] . In its native state the receptor occurs predominantly in the R conformation, maintained by intramolecular interactions within the transmembrane helical bundle, i.e. the spontaneous equilibrium heavily favors the occurrence of the inactive R state. Agonist binding, relieves these constraints, allows the receptor to 'relax' into the R* conformation allowing G-protein coupling. The extended ternary complex model developed to explain these phenomena proposes that the intrinsic efficacy of a ligand (H) is a reflection of its ability to alter the equilibrium between R and R* [11] . According to this model, Full agonists stabilize the R* conformation, tilting the equilibrium to the active state, generating full receptor activation and a maximal response; Partial agonists have lower intrinsic efficacy than full agonists, producing a submaximal response and also potential attenuation of full agonist activation; Antagonists bind indiscriminately to both R and R*, producing no physiological response but blocking the response to agonists; Inverse agonists act as antagonists in non constitutively-active systems, but have the added property of actively reducing receptormediated constitutive activity of GPCR systems by binding preferentially to R and pushing the equilibrium toward the inactive state. Even the behavior of "Protean agonists", ligands that act as partial agonists in some systems and as inverse agonists in others, can be accounted for within the extended ternary complex model if one assumes that the active receptor conformation produced by ligand binding (H-R*) is of a lower efficacy than that of the spontaneously formed R* state [12] . Under conditions of low basal activity, i.e. little or no spontaneously formed R*, such a ligand would behave as a partial agonist, while under conditions of high basal activity it would behave as an inverse agonist.
Three State to Multi-State Models
While the ternary complex model can sufficiently explain the properties of agonism, antagonism, partial agonism, and inverse agonism, it is still limited in that it accommodates the existence of only two functional receptor states. However several lines of experimental evidence suggest that multiple active states of GPCRs can exist. The first demonstrations of these were actually presented for the visual GPCR rhodopsin which was shown to adopt multiple spectral states [13, 14] . Many other GPCRs, either at physiologic levels or when overexpressed, are promiscuous in that they stimulate different signaling pathways by activating more than one G protein pool. In a two state model, where only a single R* conformation exists, the agonist pharmacology of a receptor should be the same regardless of the response being measured. Yet a paradoxical reversal of relative efficacy of agonists has been described for several GPCRs in the central nervous system that activate more than one stimulusresponse element, including the 5-HT2C receptor [15] , pituitary adenylyl cyclase-activating polypeptide (PACAP) receptor [16] dopamine D2 receptor [17] , and neurokinin NK-1 receptor [18] . Striking discontinuities of agonist efficacy have also been reported for CB1 cannabinoid receptor coupling to Gs and Gi [19] . Although differential stimulus pathway activation can occur through a 'strength of signal' type of mechanism, i.e. a highly efficacious agonist might activate two pathways whereas a weaker agonist may activate only the more sensitive one, the reversal of the relative efficacy of different agonists acting on the same receptor cannot be explained on the basis of a two state model.
In these three-state or multistate models, certain agonists are predicted to induce distinct "active" conformations of the receptor by differentially exposing regions of the intracellular domains involved in coupling to different G protein pools [20, 21] . Indeed, multiple G protein-coupled states of the 2 -adrenergic receptor can be distinguished using a variety of guanine nucleotide analogues [22] . Similarly, several receptor mutations have been described that produce constitutive activity that is restricted to a single signaling pathway among those ordinarily activated by the receptor [23, 24] . These mutations presumably restrict conformational isomerization of the receptor to a subset that promotes specific G protein coupling conformations [21, 25, 26, 27] . However these observations should be tempered with the caveat that distinct signaling varieties demonstrated using a mutated receptor may not be indicative of the true signaling potential of the receptor. Biophysical evidence also supports the concept that different GPCR ligands induce distinct populations of receptor microconformations [28, 29] . In these studies different agonists select distinct arrays of receptor conformation, consistent with the induction of ligand-selective active states.
The existence of multiple active receptor conformations makes it plausible that agonists can change not only the degree, but also the 'quality' of receptor activation. It is thus predictable that agonists producing distinct conformations of a receptor could expose different G-protein-activating sequences of the receptor so as to produce differential activation of G proteins. This multi-state model of GPCR activation provides the theoretical basis for the concept of signaling-selective agonism, also referred to as 'agonist-specific trafficking of receptor signaling' [12, 30] .
THE ORIGINS OF GPCR SIGNALING DIVERSITY
In contrast to the large number of GPCR sequences in the genome, there are comparatively few genes encoding heterotrimeric G protein subunits [31] . Many elegant experiments however have demonstrated that signal diversity and specificity can be dictated by receptor interaction with specific heterotrimeric subunit combinations [32, 33] . This review shall focus upon the conditioning of GPCR signaling induced non-G protein mediated processes. With input from a large number of receptors converging on a limited number of transducer elements, how do GPCRs generate diverse responses in the nervous system under different conditions and in different tissues?
Diversity in a Two-State Model
Although classical receptor theory allows for only a single 'active' state of the receptor, numerous factors expand the signaling repertoire of heptahelical GPCRs. First is the sheer complexity of the receptors themselves. The majority of GPCR families consist of multiple receptor subtypes, often with different G protein coupling specificities. For example, there are at least 12 different mammalian genes encoding serotonin receptors. Additional complexity derives from alternative splicing of receptor genes and RNA editing, generating multiple receptor isoforms with distinct biochemical properties from the same gene [34] .
Another layer of complexity arises from the ability of each G protein class to activate multiple downstream effectors. Both G and G subunits contribute to the modulation, in a synergistic or antagonistic fashion, of either the same or unrelated effectors, resulting in dual intracellular signaling. An example is the simultaneous Gi/o-mediated inhibition of adenylyl cyclase via the G subunit and stimulation of PLC via the G subunit [35, 36] . Further complexity arises from secondary modulation of intracellular effectors, for example the indirect activation of phospholipase A2 following a rise in intracellular Ca 2+ concentration [37, 38] .
Finally, there is the capacity for simultaneous activation of multiple G protein pools. Some Gi/o-coupled receptors, for example, mediate phosphoinositide hydrolysis through a pertussis toxin-insensitive pathway in addition to mediating pertussis toxin-sensitive inhibition of adenylyl cyclase [39, 40] . The dual coupling to Gs and Gq/11 family G proteins [41] or to Gi/o and Gq/11 family G proteins [42] [43] [44] has now been reported for many GPCRs. In some cases, a single receptor has been found to simultaneously activate members of three or even four unrelated classes of G protein (Gs, Gi/o, Gq/11, and G12) [45] .
A persistent question is whether multiple G protein coupling represents pleiotropy, i.e. physiologic activation of different G protein species, or promiscuity, i.e. low efficacy activation of non-preferred G protein species as a result of receptor or G protein overexpression. In experimental systems, an agonist activating one GPCR that stimulates multiple G proteins frequently elicits signals downstream of each G protein with differing efficacy and/or potency [43] . Unless there is reversal of agonist efficacy, such behavior is consistent with a two state model in which the receptor can interact with both preferred and secondary transducers. Indeed, emergence of a dual signaling commonly occurs as the level of receptor expression increases, e.g. pathologically, suggesting that most GPCRs are promiscuous [46, 47] . Similar phenomena arise from changes in the expression levels of the participating G proteins [48] . On the other hand, many studies have demonstrated dual or multiple coupling in systems where the GPCR is constitutively expressed at low levels, consistent with physiologically relevant pleiotropic G protein coupling [44, 49] .
Diversity Due to Multiple Receptor Conformations
Consistent with models of agonist-specific trafficking of receptor signaling, a number of structurally modified agonists for promiscuous peptide and non-peptide GPCRs have been shown to promote selective G protein coupling [50, 51] . A similar phenomenon is signal-selective antagonism, in which an antagonist blocks only a subset of the signaling pathways elicited by an agonist. This has been clearly described for the cholecystokinin CCK-B [52] and neurokinin NK-1 receptors [53] . Other examples of ligand-selective GPCR regulation include ligands that promote coupling to one G protein pool while antagonizing coupling to another. The gonadotropin-releasing hormone (GnRH) receptor 'antagonist' Ant135-25 acts as an antagonist with respect to Gqcoupling by the GnRH receptor, but functions as an agonist in cellular contexts where the receptor is coupling to Gi [54] . Similarly, the 2-adrenergic receptor 'antagonist' ICI-118-551, which behaves as an inverse agonist for coupling to Gs [9] , was recently found to act as an agonist for 2-adrenergic receptor coupling to Gi [55] .
Studies of agonist-induced GPCR desensitization and endocytosis have likewise demonstrated the existence of ligand-specific receptor conformations. In a two-state model, it would be expected that the relative propensity of agonists to induce desensitization would parallel their relative efficacy for signaling. For μ opioid receptor agonists this is generally true, with the notable exceptions of methadone, L--acetyl methadone, and buprenorphine, which induce disproportionate receptor phosphorylation and desensitization [56] . Similarly, both enkephalins and morphine stimulate and μ opioid receptors, but only enkephalins induce rapid receptor internalization [57] . Disparities between primary pathway activation and desensitization have been also demonstrated for neurokinin NK-1 [58] and serotonin 5-HT 2C receptors [59] . Studies of the recovery from desensitization also suggest that agonists differentially affect receptor conformation. Whereas the resensitization of 5-HT 3 receptors after prolonged stimulation with partial agonists is mono-exponential, desensitization induced by full agonists recovers with sigmoid kinetics, suggesting at least 3 transitional steps and up to 4 states [60] . Even more dramatic are GPCR 'antagonists' that stimulate receptor internalization. The cholecystokinin (CCK) receptor antagonist D-Tyr-Gly-[(Nle28,31,DTrp30)cholecystokinin-26-32]-phenethylester, which blocks CCK-mediated G protein activation, nonetheless causes profound receptor internalization [61] . The finding that synthetic ligands can induce two or more functionally distinct receptor conformations suggests the possibility that native hormones interacting with the same GPCR may exhibit agonist-specific trafficking. Does this phenomenon occur in nature? Some data suggest so. For example CCL19 and CCL21, two endogenous chemokine Type 7 receptor ligands that exhibit equivalent potency and efficacy with respect to calcium mobilization differ dramatically in terms of their ability to cause receptor phosphorylation and desensitization [62] .
It is therefore clear that GPCR ligands can condition the quality of the receptor activation event through control of structural reorganization. These ligands mentioned in this section typically interact with the classical ligand pore upon the receptor. This classical hormone-interacting site, typically in the helical bundle for small biogenic amines or on the superficial extracellular loops and regions of the helical core for small neuropeptides, is known as the orthosteric binding site. GPCRs, however, like ligand gated ion channels such as the GABA A or NMDA receptor, possess additional ligand 'binding' sites that can allosterically affect receptor function. Compounds, different from the original cognate ligand, that interact with these allosteric sites on GPCRs can serve to potentiate or attenuate the activity of the endogenous ligand at the receptor [63] . Therefore the presence of such sites may additionally expand the diversity of signaling behavior that can be seen through GPCRs.
Diversity Arising from Receptor Dimerization
Co-precipitation studies, complementation experiments using mutated or chimeric receptors, and fluorescence energy transfer measurements all support the hypothesis that many, if not most, GPCRs can form homodimers, heterodimers, or higher order multimers [64] . The assembly of receptor multimers establishes another level of conditioning that can affect GPCR ligand recognition, signaling, and intracellular trafficking. In the limit case, receptor dimerization is a prerequisite for the functionality of the receptor. Theamino butyric acid type B (GABA B )R1 and GABA B R2 receptors are nonfunctional as monomers. Only GABA B R1-R2 heterodimers are capable of membrane expression and signaling [65] . Dimerization of the μ and opioid receptors decreases the affinity for certain agonists [66] whereas the converse is true for heterodimers of the adenosine A2A and dopamine D1 receptors, where selective agonist affinities are increased [67] . Agonist efficacy can also be altered by GPCR dimerization [68, 69] . For example, heterodimerization between somatostatin SSTR5 and SSTR1 and also between μ and opioid receptors, increases both the intrinsic efficacy and the apparent potency of some agonists [70] .
Cross talk between heterodimeric GPCR pairs can positively or negatively modulate the response to agonist binding resulting in either enhanced G protein activation or crossinhibition [71] [72] [73] . Even qualitative changes in G proteincoupling specificity have been reported. Whereas μ and opioid receptors couple to pertussis toxin-sensitive Gproteins when expressed individually, co-expression of these receptors results in opioid signaling in the presence of pertussis toxin [66] . Finally, heterodimerization can affect receptor desensitization and trafficking, thus modulating the duration of GPCR signaling, e.g. the nonselective opioid agonist etorphine, which causes internalization of , but not opioid receptors, does not cause opioid receptor internalization when it is co-expressed with the receptor [73] .
Non-Receptor Modifiers of GPCR Signaling
The pharmacology of at least two neuronally expressed GPCRs is determined not exclusively by the structure of receptor alone, but by their interaction with the non-receptor RAMP (Receptor Activity Modifying Protein) and RCP (Receptor Component Protein) proteins [74, 75] . RAMPs form complexes with the calcitonin receptor-like receptor (CRLR) and calcitonin receptor and control receptor trafficking and function. The specific CRLR-RAMP complex determines the ligand specificity and expression of the receptor. The CRLR-RAMP1 complex acts as a receptor for the calcitonin gene-related peptides, a pleiotropic family of neuropeptides with homology to calcitonin, amylin and adrenomedullin. When CRLR is co-expressed with RAMP2 and RCP it functions as an adrenomedullin receptor. Similarly, complexes between a naturally occurring splice variant of the calcitonin receptor and RAMP1 or RAMP3 yields the functional amylin receptor. RAMP expression is modified under physiologic stress and in response to glucocorticoids, suggesting that cellular responsiveness to certain hormones can be regulated through the control of accessory protein expression [76] [77] [78] .
Desensitization as a Modifier of Signal Quality
Mechanisms to dampen GPCR signals exist at multiple levels. At the receptor level, two processes, termed heterologous and homologous desensitization, respectively, have been shown to control not only signal duration and intensity, but also signal quality. In heterologous desensitization the activation of second messenger-dependent protein kinases, such as protein kinase (PKA) and PKC, leads to phosphorylation of serine and/or threonine residues in the cytosolic loops and C-terminal tail of many GPCRs inhibiting receptor-G protein coupling. Agonist occupancy of the receptor is not required [79] . In contrast, homologous desensitization is specific for agonist-occupied GPCRs. It is a two-step process in which the receptor is first phosphorylated by one of a family of G protein-coupled receptor kinases (GRKs), then binds to an arrestin protein that exhibits high affinity only for the agonist-occupied, GRK-phosphorylated form of the receptor. Arrestin binding serves to both sterically inhibit G protein coupling and to target the receptor to clathrin-coated pits for internalization [80] .
Receptor phosphorylation can alter the specificity of G protein coupling to a receptor e.g. PKA phosphorylation of S357 of the Gs-coupled prostacyclin receptor is required for alternative coupling to Gi and Gq/11 [81] . Other GPCRs demonstrate type selective desensitization of G protein coupling following PKA or PKC activation, e.g. Gq/11-mediated glutamate release by the subtype 1a metabotropic glutamate receptor (mGluR1a) is progressively desensitized by PKC-mediated receptor phosphorylation, while a simultaneous inhibitory signal mediated through Gi/o coupling remains unaffected. The result is that in the presence of a persistent stimulus, the mGluR1a receptor switches from an activator to an inhibitor of glutamate release [82] . Collectively, these data suggest that regulation of the G protein coupling specificity by receptor phosphorylation adds an additional level of control that permits the temporal resolution of cellular signaling elicited during the sustained stimulation of a receptor.
GPCR Coupling to Non-G protein Effectors
A final source of GPCR signaling diversity arises from data suggesting that GPCRs transmit 'G proteinindependent' signals, and that coupling to certain non-G protein effectors exhibits features consistent with agonistspecific trafficking.
The intracellular domains of several GPCRs have been shown to bind to proteins that might function as alternative GPCR signal transducers, among them guanine nucleotide exchange factors (GEFs) for small G proteins, nonreceptor tyrosine kinases, and several proteins that function as adaptors or scaffolds [83] . A specific peptide motif in the Cterminus of the 1-adrenergic receptor binds directly to the PDZ domain (named from Post synaptic density protein of 95 kDa (PSD95) -Discs large -Zona occludens proteins) domain of the cAMP-regulated Ras GEF (CN-Ras GEF), allowing the receptor to stimulate guanine nucleotide exchange on the small G protein, Ras [84] . Stimulation of the JAK-STAT pathway of transcriptional regulation by angiotensin AT1a receptors involves tyrosine phosphorylation of AT1a receptor tail by a Src family kinase, followed by association of JAK2 with the receptor. In this case, the binding of JAK2, which does not have a phosphotyrosine-binding SH2 domain, appears to be indirect, and may be mediated by a member of the SHP family of SH2 domain-containing tyrosine phosphatases [85] .
However the most compelling evidence to date for 'G protein-independent' signaling involves the utilization of arrestins as alternative signal transducers. The two nonvisual arrestin isoforms ( -arrestin 1 and 2) can bind to several signaling proteins and recruit them to agonist-occupied GPCRs [86, 87] . Src family nonreceptor tyrosine kinases [88, 89] , components of the c-Jun N-terminal kinase 3 (JNK3) and ERK1/2 MAP kinase cascades [90] [91] [92] and the PDE4D3 and PDE4D5 isoforms of cAMP phosphodiesterase [93] are recruited to GPCRs in this manner. In this distinctive model of GPCR signaling, -arrestin binding is thought to confer enzymatic activity upon the receptor at the same time that it uncouples the receptor from its cognate G proteins. Indeed, the finding that arrestin-bound m2 muscarinic acetylcholine receptors (m2AChR) exhibit increased affinity for agonists, but not antagonists, has led to speculation that the agonist-receptor-arrestin complex represents an 'alternative ternary complex' [94] . For GPCRs, like the NK-1, AT1a, and V2 vasopressin receptors, all of which form stable GPCR-arrestin complexes, the -arrestin-dependent 'signalsome' appears to remain intact as the receptor transits the endosomal compartment, resulting in activation of a spatially-constrained, extranuclear pool of activated ERK1/2 [92, 95] . In contrast, G protein-dependent ERK1/2 activation tends to promote nuclear translocation of the kinase and ERK1/2-dependent transcriptional responses. Thus signal strength, duration, subcellular localization, and functional consequence are all dictated by the mechanism of signal propagation.
THE ORIGINS OF SIGNALING SPECIFICITY
The converse of signaling diversity is signaling specificity, the constraint of responses to specific cells or nervous tracts, even when the stimulus itself may be neuromodulatory, as in the case of a secreted neuropeptide hormone. In essence, there must be mechanisms to limit 'signal spread' and work against promiscuity.
There are numerous factors, both intracellular and extracellular, with the classical conceptualization of GPCR signaling that promote specificity. For example, the highly localized release and rapid reuptake or extracellular degradation of neurotransmitters within the synaptic space provides a highly effective means of confining signals spatially. For neuromodulatory hormones, neuron-selective expression of receptor subtypes comes into play. A typical cortical neuron may express more than ten different GPCR genes, different combinations of G protein subunits, and multiple isoforms of effector molecules. The differential expression of these various proteins imposes signal specificity at many levels, resulting in hormone responses that are customized for the specific cell type. Signal duration and intensity are selectively modulated through rapid receptor desensitization and internalization, and more slowly by downregulation of receptor expression [96] . Nonetheless, GPCR signaling systems appear to exhibit higher levels of preorganization than can be accounted for by control of ligand availability and neuronspecific expression of transducer elements. Numerous studies have indicated that different GPCRs coupling to the same G protein in a single cell can elicit different biochemical or cellular responses [97] [98] [99] [100] [101] [102] . A one-dimensional view of GPCR signal organization cannot readily account for such observations. At least two additional factors, compartmentalization of signaling proteins within membrane microdo-mains and preorganization of GPCR signaling units through interactions with anchoring and scaffolding proteins, appear to play important roles in neuronal GPCR signaling specificity.
Specificity Arising within Membrane Microdomains
For most of the early years, GPCR signal transduction was conceptualized along the lines of a 'Brownian motion' model in which the random thermodynamic collision of signaling proteins within the plane of the plasma membrane was responsible for the flow of information from receptor to G protein to effector. Such a random process, however, would be energetically expensive for complex organisms that require rapidity and specificity of neuronal signaling function. Furthermore, mounting experimental evidence indicates that GPCRs, G proteins, and effectors are not randomly distributed in the plasma membrane. Indeed, it has been suggested that GPCR signaling mainly occurs within specialized microdomains, implying that the efficiency and specificity of signal transduction are dictated by the stoichiometry of transducer elements within spatially discrete membrane regions [103, 104] .
One of the most studied forms of membrane microdomain in neuronal tissue are regions of high density cholesterol, gangliosides and sphingolipids referred to as caveolae or lipid rafts [105] . Many GPCRs and their associated signaling proteins, such G proteins, RGS proteins and non-receptor tyrosine kinases like c-Src, have been shown to localize to these structures, often aided by C-terminal palmitoylation. A striking example of how localization of a GPCR within lipid microdomains can dictate signal selectivity is the neuropeptide oxytocin receptor. When present in caveolae the receptor exerts a proliferative effect upon HEK293 cells through a Gq-mediated mechanism involving cross talk with epidermal growth factor (EGF) receptors that also concentrate in caveoli. Oxytocin-stimulated EGF receptor 'transactivation' is independent of PLC, c-Src or phosphoinostide-3 kinase (PI3-K) activity. In contrast, activation of oxytocin receptors outside of rafts produces the exact opposite effect, an inhibition of cell proliferation that is Gi-, PLC-, c-Src-and PI3-Kdependent [106] . In addition to lipid rafts, other regions of the plasma membrane where signaling proteins are aggregated, such as focal adhesion complexes and clathrin-coated pits, appear to serve as sites of GPCR signal integration and specificity.
Scaffolding and Preorganization as Determinants of Signal Specificity
It is now clear that the intracellular domains of GPCRs participate in numerous interactions with cellular proteins that serve to organize the partners in a signaling cascade [107, 108] . In essence, these scaffolds assemble GPCRs, G proteins, effectors and downstream elements into prearranged 'solid-state' signaling devices that impose crucial spatial resolution and signaling compartmentalization on GPCR-mediated signaling systems. It is clear how important such organization is in complex cells such as cortical neurons, as their multiple regions have specific functions such as the soma, axon and terminal dendrites. For example, 2-adrenergic receptors have a well documented association with plasma membrane AKAP (A kinase anchoring proteins) proteins [109] . AKAPs act as dynamic platforms that orchestrate the interactions of protein kinases, including tyrosine kinases, protein phosphatases, e.g. calcineurin, and cytoskeletal elements with 2 receptors. Other preformed complexes between the 2 receptor and potential effectors have been reported, including association with the EGF receptor, a target for GPCR-stimulated 'transactivation' [110] , and recently with the BKCa large conductance Ca 2+ -dependent potassium channel [111] .
Recently, a number of neuronal PDZ domain-containing proteins have been shown to interact with the distal Cterminus of select GPCRs and direct the assembly of functional synaptic protein networks [112] . This pre-organization of GPCRs into 'signalsomes' appears to be particularly prevalent within the central nervous system, where signaling efficiency and spatial constraint are paramount. Synaptically enriched proteins such as PSD-95, membrane-associated guanylate kinase inverted-2 (MAGI-2), SH3 multiple ankyrin domain-containing protein (Shank)/somatostatin receptor interacting protein (SSTRIP), Protein interacting with C kinase 1 (PICK-1), multi-PDZ domain protein 1 (MUPP1), and spinophillin contain between one and thirteen PDZ domains and all can associate with GPCRs forming higher order structures [113, 114] . Their association with many GPCRs, e.g. mGluRs, serotonin and adrenoceptors, has been reported to modulate such diverse functional properties as receptor dimerization, subcellular localization, effector coupling, and trafficking. For example the Homer proteins, which are involved in the control of actin filament dynamics, interact with polyproline sequences found in mGluR1 , mGluR5 metabotropic glutamate receptor [115] , Shank/SSTRIP, IP3 receptors [116] , ryanodine receptors [117] , and P/Q type calcium channels. Homer proteins function in the organization of postsynaptic glutaminergic sites, and excitation-dependent expression of Homer isoforms affects mGluR trafficking and targeting to axons and dendrites [118] . The dopamine receptor-interacting protein of 78 kDa (DRIP-78) binds to a C-terminal hydrophobic motif in D1 dopamine receptors and controls post-translational processing of the receptor [119] . The actin-binding protein 280 (ABP-280 or filamin A) interacts with the third intracellular (IC3) loop of the D2 and 3 dopamine receptors. ABP-280 binding fosters D2 receptor clustering at the plasma membrane and enhances the ability of D2 receptors to inhibit adenylyl cyclase. The 14-3-3 proteins, a family of at least seven acidic brain proteins that bind to phosphorylated serine/threonine motifs, interact with the third intracellular loops of 2 adrenergic [120] and GABA B R1 receptors [121] and appear to regulate GPCR dimerization, activation of the Ras/Raf cascade, and the localization of regulator of G protein signaling (RGS) proteins. Collectively, these examples illustrate the extent to which scaffolding protein interactions preorganize GPCR signals and ensure signal fidelity in neuronal systems.
GPCR SYSTEMS IN ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease known in industrialized nations, at least four million US citizens are currently afflicted with the disease. It is estimated that without effective prophylactic treatment this number could rise to fourteen million by 2050 [122] . One major risk factor for AD is aging itself, however this is a natural process that is largely resistant to therapeutic intervention. The aging process involves complex changes in physiology resulting in great variations of expression or post-translational modification of a multiplicity of proteins. As we have seen in this review one must accept that GPCR function is dependent on many other protein factors outside the heptahelical core. Therefore the number of potential changes in GPCR functionality expands dramatically once one appreciates the myriad of protein factors that control GPCR pharmacology through the creation of discrete 'signalsomes' in the nervous system. While the processes that underlie the generation of hallmark AD pathologies, hyperphosphorylated tau and amyloid plaques, have been intensively studied, several important GPCR-related factors appear to play important roles in AD genesis and progression. With respect to the design of prophylactics or therapeutics, it is important to understand the potential changes in receptor pharmacology that may occur with aging itself and the pathological neurophysiological changes that occur in AD. An important caveat however needs to be inserted here in that we have shown earlier in this review that accessory proteins definitely can define GPCR signaling. However whether these alterations and their resultant effects signaling play an important and pervasive role in pathophysiologies remains to be full ascertained. We shall briefly discuss the relevance of GPCR factors in AD and then, with an eye to understanding how GPCR function is dependent on 'signalsome' complexity, attempt to rationalize novel therapeutic strategies to encompass this new model of pharmacology. Theoretically it should be possible to generate therapeutics with either an enhanced efficacy in certain physiological conditions, e.g. the aging patient, or selective efficacy for diseased states, e.g. AD, compared to normal physiological states.
A panoply of GPCR systems have been implicated in the etiology and pathology of AD. A small selection is shown in Table 1 , however a caveat must be added with respect to lists larger than this, as these alterations in GPCRs could be merely reactive to the disorder and may not play an active role in its genesis. In the central nervous system (CNS), receptor signaling specificity and diversity has facilitated the creation of an unimaginably complex neurotransmitting system. In rudimentary terms the neurotransmission in the CNS consists of a small number of basic signaling modalities that are conditioned by a much greater number of subtle neuromodulating neurotransmitters. The primary signaling events controlling neuronal excitability occur through amino acid modulation of ligand-gated ion channels, e.g. excitatory glutamate (NMDA, AMPA and Kainate) receptors and inhibitory GABA A receptors. Hormones acting at a multitude of GPCRs tend to exert more subtle neuromodulatory actions, adding 'texture' to the primarily 'binary' amino acid ligandgated ion channel mechanism. The colossal variety, up to 60, of neuromodulatory agents, compared to the primary excitatory and inhibitory amino acids, hints at their importance in generating signaling complexity in the CNS. It is clear that many of the GPCR systems that possess a role in AD can show specificity of expression, e.g. dendritic, post-or presynaptic etc. The selectivity of subcellular expression likely facilitates the generation of multiple GPCR receptorsomes that confer disparate functions to the same heptahelical core. Clearly, as seen in (Table 1) , a vast array of GPCR-based systems could be involved in the aetiology of AD, yet for the purposes of this review we shall focus on the latest data on the more pharmacologically tractable targets with respect to our new knowledge of how receptor specificity and signaling diversity is generated.
Unfortunately for traditional receptor biochemistry two of the major classical targets of pharmacological intervention for AD, the muscarinic acetyl choline (ACh) and glutaminergic receptor systems consist of multiple receptor subtypes that bind the same small endogenous ligands, ACh and glutamate, with great similarity. In addition to these traditional therapeutic targets several new lines of evidence have shown the importance of the serotonergic GPCR system in AD. As with muscarinic and glutaminergic GPCRs there are a plethora of serotonin receptor subtypes present in the brain which all again bind serotonin with similar affinity. Therefore generation of signaling-and subtype-specific agents has proved to be difficult due to the commonality of ligandreceptor interactions at heptahelical cholinergic muscarinic, serotonergic and glutaminergic GPCRs. We shall discuss how understanding of how GPCR structure and function may be altered with accessory protein binding the creation of tissue-specific or even pathology-specific compounds may be facilitated.
CHOLINERGIC GPCR SYSTEMS IN ALZHEIMER'S DISEASE
One of the primary neurophysiological alterations that appears to occur in AD is the loss of cholinergic function in cortical and hippocampal brain areas [123] . Therefore the muscarinic receptors (m1-m5AChR subtypes) have been implicated in controlling the regulation of memory, learning processes and cognition. The cholinergic hypothesis of Alzheimer's has been exploited with therapeutics targeted towards elevating the pathologically lower levels of ACh observed in AD patients [for review see 124] .
For example the expression of pre-synaptic m2AChR, an autoreceptor that controls ACh release, appears to be altered in AD [125, 126] . Current treatments for AD often involve increasing acetylcholine levels in the synapse through administration of acetylcholinesterase inhibitors. An alternative approach would be the administration of selective m2AChR antagonists to elevate the levels of ACh in the synapse. If the pre-synaptic m2AChR was held in a different conformation than others expressed in different cellular locations it should be possible to generate pre-synaptic-specific therapeutics.
With respect to the m1AChR, selective activation could provide potential benefit through a variety of mechansims, e.g. amelioration of the cholinergic neurotransmission deficit, activation of -secretase (non-amyloidogenic APP processing) and inhibition of tau phosphorylation [for review see 127] . Muscarinic receptor signaling in general can also affect beta-amyloid cleaving enzyme (BACE1) function. Selective stimulation of m1/m3AChRs elevates expression of BACE1 while stimulation of m2AChRs reduces the expression of BACE1, thus confirming from another angle the potential value of m2AChR inhibition [128] . Ameliorating the cho- Chemokine receptors Upregulated Cortex Neuroinflammation [187] linergic signaling deficit in AD m1AChR activation may also directly attenuate the deleterious effects of A peptide upon neurons. m1AChR-mediated inhibition of GSK3 can stabilize cytoplasmic -catenin resulting in an elevation of the Wnt target genes, engrailed and cyclin D1, that functionally antagonize the inhibition of the Wnt pathway induced by A peptide [129] . Selective m4AChR receptor stimulation may even have a beneficial action on the psychotic components of AD [130] . An understanding of how the similar mAChRs are organized into superstructures may facilitate the ability to design agents that act at specific subtypes in particular subcellular locations.
Reinforcing its importance in AD the cholinergic system is subject to a great degree of modulation by other GPCR systems. Endogenous modulation of the cholinergic transmitter system in the hippocampus, the primary region of AD pathology interest, is primarily mediated through GABAergic mechanisms. It has been previously demonstrated that the G protein-coupled GABA B receptor may represent an important target for therapeutic design as early GABA B receptor antagonists show a capacity to improve cognitive function in a variety of animal models [for review 131] . Recently a specific GABA B receptor antagonist, SGS742, has shown therapeutic promise by improving cognitive function in a double-blind Phase II trial of patients with mild cognitive impairment [132] . As we have discussed it is likely that there are many functional GPCR homodimers or heterodimers that contribute to the 'true' receptor pharmacology phenomena that has been observed. As GABA B receptors exist functionally as dimeric molecules they present an excellent target for the creation of novel ligands that specifically recognize this new state of the molecule and may possess a whole new pharmacology compared to existing GABAergic agents. The screening process for compounds with specific activities at dimeric receptors however may necessitate the creation of covalently linked receptors to negate the presence of non-dimeric receptor forms. It is possible therefore that the creation of new ligand binding epitopes, ortho or allosteric, may occur with dimerization that could allow a novel form of control of receptor activity.
The actual connectivity of mAChRs with their G protein and other signaling systems are significantly downregulated in the frontal cortex of AD patients suggesting an alteration in the physicochemical structure of the receptor signalsome itself, 'decompartmentalising' it from its transduction machinery [133] . In addition to alterations of m2AChR signalsome structure, with the m1AChRs there is a disruption of the compartmentalization of its connection to its cognate RGS protein and Gq/11 protein [134] . The AD pathogenic alteration of the amyloid processing pathway itself may serve to modify GPCR signaling systems, as it has been demonstrated that mutations in presenilin 1 (PS1) can functionally attenuate intracellular phospholipase C signaling induced by muscarinic receptor activation, potentially contributing to the effective cholinergic deficit associated with AD [135] .
Not only is the GPCR connection to signaling machinery in its receptorsome impaired in neurodegenerative diseases but also the regulatory processes affecting GPCRs have been implicated. For example, plasma membrane GRK2/5 activity is significantly reduced in pre-symptomatic AD mouse cortex [136] . This loss of regulation may result in cellular hyperstimulation by numerous GPCR inputs. One example of hyperstimulation is excessive proteinase activated receptor (PAR)-mediated microglia activation or tau hyperphosphorylation in hippocampal neurones [137] . Proteinase-activated receptors (PARs) potentially play a dual role in promoting both neuronal survival and causing neurodegeneration. Ligands activating the PAR receptors have been shown to protect astrocytes and neurons [138] . There has been a significant degree of interest in the -arrestin-dependence of PAR receptor signaling since connections between the receptor and its signaling scaffolds determines the eventual nature of the transduced signal. Excessive stimulation may entrain enhanced -arrestin inclusion into the receptorsome causing a dynamic disruption of the correct multi-protein complex stoichiometry and re-direction of signaling into G proteinindependent pathways.
SEROTONERGIC GPCRS IN ALZHEIMER'S DISE-ASE
Recent evidence has suggested that compromised serotonergic function, in addition to its well-known role in depression, may play an important role in cognitive decline in aging, AD and also schizophrenia. Complex changes appear to occur to 5-HT receptor systems in AD, which could open up avenues for the development of therapeutic agents to control AD symptomology. Serotonergic receptors have been found to occur in large receptorsome structures and it is highly likely that alterations in the receptor structure could affect the stoichiometry of these entities. Of particular interest is the observation that polymorphisms of the 5HT 2A receptor are strongly correlated with the presence of psychotic symptoms in AD [139] . Subtle changes in the helical core structure introduced by these polymorphisms may not significantly affect ligand binding and G protein signaling but may facilitate the creation of polymorphism-specific 5HT receptorsome complexes. Hence the change in structure of the receptor may only affect accessory protein binding, creating a specific receptorsome complex that possesses distinct signal transduction patterns compared to wild-type receptor complexes.
Serotonergic signaling systems have been shown to productively interact with the cholinergic signaling system in the brain, thus reinforcing their importance for AD research. Activation of somato-dendritically located 5-HT 2A receptors facilitates substance P (SP) release. SP, in turn, stimulates hippocampal ACh release through activation of tachykinin NK 1 receptors present on cholinergic terminals [140] . Pertinent to development of novel serotonergic AD therapeutics, several receptor subtype-specific perturbations of serotonin receptor function have been observed in AD. For example 5-HT 1B / 1D and 5-HT6 receptors are downregulated in the frontal cortex of AD positive patients [141] . Importantly the 5-HT6 receptor appears to be predominantly post-synaptic in its expression and may be concentrated in GABAergic spiny neurons, which exert potent inhibitory actions upon excitatory glutaminergic neuronal circuits. Recent evidence has also suggested that selective 5HT 1A, 4 and 7 ligands can enhance memory formation and thus may form the basis of future cognitive therapeutics [142, 143] . For example, Lecozotan is able to mediated an enhancement of stimulated glutamate and ACh release through selective inhibition of 5HT1A receptors, resulting in a positive cognitive-enhancing action [144] .
Generation of discrete receptor-and signaling-specific agonists against various 5HT-receptor subtypes may enhance the efficacy of serotonergic compounds for AD. Due to the complexity of the 5HT deficits/dysregulation in AD rather than using a series of 'selective' compounds it may be prudent to develop individual 'pluri-protean' serotonergic agents that display a variety of 'pharmacologies' dependent upon the type of neuron expressing the 5HT receptor and also the specific 5HT receptor subtype. Multi-receptor modulatory agents, that have agonistic capacities on some receptor subtypes and antagonistic actions on others may represent a more efficacious mode of therapeutic development.
METABOTROPIC GLUTAMATE GPCRS IN ALZ-HEIMER'S DISEASE
Neuronal excitotoxicity has been proposed to be involved in the pathogenesis of chronic neurodegenerative disorders, such as Parkinson's and Huntington's diseases as well as AD. It is accepted that modulation of the stimulatory glutaminergic neurotransmission could be used as a direct therapeutic for these disorders. Hence metabotropic glutamate receptors (mGluRs) may be relevant targets for intervention of neurotransmitter-mediated excitotoxicity in degenerative disorders. There are up to eight different subtypes of metabotropic glutamate receptors typically expressed in the CNS. All of these members have a high degree of amino acid conservation in the ligand binding pocket and thus bind glutamate in a similar manner between the multiple subtypes. These secretin-like Class II GPCRs control neural excitability and also neurotransmitter secretion. A down-regulation of mGluR binding sites has been reported in post-mortem AD brains [145] . The possibility of a protective role for the mGluR system in the nervous system has led to significant interest in agents that control glutaminergic signaling. mGluR activation prevents and, in some cases, reverses genomic DNA degradation [146] , regulates the metabolism of APP, accelerates the processing of APP into nonamyloidogenic APP [147] and can enhance the release of the neurotrophic secreted form of processed amyloid precursor protein (sAPP) [148] . Reinforcing the recurring theme of GPCR signaling complexity, under some circumstances, diminished activity of mGluRs may even prove useful for cellular protection. For example, inhibition of group II mGluRs can attenuate microglial activation and subsequent neurotoxicity during toxic stimuli such as chromogranin A [149] , a protein up-regulated in Alzheimer's disease. mGluRs are also believed to be necessary for the processing of learning and memory [150] . Activation of pre-synaptic group II/III mGluRs can inhibit glutamate secretion, reducing the neuronal excitotoxicity linked to excessive glutamate release. Therefore, selective mGluR agonists may provide neuroprotection and neuronal restoration by decreasing excitotoxic events and enhanced neurotrophic support. On the other hand, selective mGluR antagonists might alleviate deficits in synaptic transmission in AD by preventing this inhibitory feedback on glutamate release.
Interestingly, mGluRs are expressed and function specifically as dimeric molecules tethered together by their large extracellular N-termini. Full receptor activation requires two glutamate molecules interacting with both receptors of the dimer. Monomeric activation can occur but does not yield the full spectrum of receptor activation seen with dimeric activation [65] . Therefore hybrid molecules containing two different entities, either fully or partially agonistic or even antagonistic, could be created using small molecular linkers between the two modulating ligands.
Metabotropic glutamate receptors can not only homodimerize but can also form functional heterodimeric signaling units with other GPCRS, e.g. adrenoceptors, adenosine receptors (A 2A ), dopamine receptors (D2) and muscarinic receptors [for review see 151] . The potential to create hybrid multi-functional ligands, that differentially activate one or both of the pharmacologically-distinct dimerized receptors, is yet another test-bed for novel drug discovery strategies.
Drug discovery over recent years has focused upon the development of selective ligands that manipulate the target receptor by interacting with the epitopes on the receptor that the endogenous ligand interacts with, i.e. the 'orthosteric' modulatory site of the receptor. As mentioned earlier, it has proven problematic to generate mGluR ligands that are selective and specific in action due to the high level of sequence conservation between the eight mGluR subtypes in the agonist binding pocket and glutamine binding affinities. This, along with the difficulty of delivering charged amino acids through the blood-brain barrier, has hampered the development of 'orthosteric' mGluR-interacting ligands and the potential therapeutic benefit of such compounds remains to be realized. In contrast small inorganic compounds that bind allosterically to the GPCR have been shown to control GPCR activity in both synergistic and antagonistic capacities. Higgins et al. [152] found that LY354740, a positive allosteric regulator of mGluRs, impaired learning in the Morris Water Maze model, whereas an antagonist (LY341495) improved acquisition of spatial learning. In line with this, group I mGluR antagonists/negative allosteric modulators may show promise for neuroprotection in AD.
The importance of creating allosterically-acting GPCR ligands may be critical for AD therapeutics as the primary targets, e.g. mAChR, mGluR and serotonin receptors, have demonstrated a resistance to generating subtype-selective orthosteric ligands. Allosteric modulators tend to only have effects in the presence of the orthosteric ligand, e.g. ACh, glutamate or 5-HT, however such agents may have a specific advantage for the treatments of disorders characterized by neurotransmission deficits such as AD. Such modulators might selectively enhance the effects of the endogenous GPCR ligand without disrupting the normal temporal and spatial profile of neurotransmitter release. Therefore subtle memory or motor patterns, based upon existing neurotransmission circuits would likely be retained. With respect to AD, the failure of orthosteric compounds as effective therapeutics may be due to a disruption of the release patterns of the endogenous agents that entrain proper neurophysiological activity. This 'artificial' modulation of neurotransmitters is more likely to induce desensitization or downregulation of the receptor systems they are attempting to modulate as the compounds may be continuously present rather that occurring at the correct synaptic concentration for the correct period of time. Therefore it is likely that true sub-type selectivity of muscarinic, glutaminergic or serotonergic agents may only be generated by targeting them to regions of the receptor protein outside of the highly-conserved orthosteric binding site. This seems feasible as the majority of allosteric modulatory sites in GPCRs occur in the less well conserved regions of the receptor, i.e. the extracellular loops and the superficial regions of the transmembrane helices. Many allosteric modulators that selectively modify signaling by receptor subtypes expressed in the CNS, e.g. mGluR 1, 4, 5; mAChRs, 5HT type 1B, 1D, 2A, 2C and 7 receptors, have been developed [153] . It is hoped that these agents could form the building blocks for the next generation of AD therapeutics.
THERAPEUTIC IMPLICATIONS OF RECEPTOR THEORY
Data continues to emerge indicating that GPCR signal transduction is both more diverse and more specific than originally imagined. The existence of multiple 'active' receptor states, of receptor-receptor and receptor-scaffold interactions that modify receptor pharmacology, of possible 'G protein-independent' signaling, and of tissue selective preorganization of signals, presents the opportunity to develop drugs that induce only a subset of the GPCR response profile. At the same time, signaling complexity implies the existence of pitfalls arising from unintended drug action. Not only do these additional protein factors allow specificity of signaling in the CNS but they also may underpin the generation of physiological phenotypes such as the aging process or be part of the etiology or the reactive response to neurodegenerative processes. The influence of external factors on character of GPCR signaling may generate diverse receptor pharmacologies that can engender the derivation of entirely new therapeutic pharmacopeias specifically tailored to these individual states, thus creating the field of 'expetopharmacology' from the latin for 'to design for'.
The potential therapeutic implications of agonistselective signal trafficking extend beyond just the regulation of the receptor-G protein coupling event. For example, ligands that selectively induce receptor activation without inducing any significant internalization could be beneficial in treatment of psychopharmacological drug tolerance [56, 154] . Similarly, selective GPCR internalization may prevent HIV-1 infection through chemokine receptor fusion. Ligands that cause internalization of CXCR4 [155, 156] or CCR5 [157, 158] have been shown to protect against HIV-1 infection in vitro. Selective removal of chemokine receptors from the cell surface could be superior to blocking chemokine receptor interaction with HIV viral coat proteins because it would prevent the possible rapid emergence of resistant HIV variants through therapeutic pressure and mutation [159] [160] [161] . Receptor dimerization may also generate therapeutic targets with unique pharmacology and signaling characteristics. Receptor dimers have been implicated in numerous areas including HIV-1 infection [162, 163] and the function of neuroprotective cannabinoid receptors [164] , GABA-B receptors [165, 166] , adenosine A1 receptors [167] , -opioid receptors [168] , 2 -adrenoreceptors [68] , and calciumsensing receptors [169] . Drugs that selectively target unique ligand-binding pockets generated through dimerization may produce effects not associated with monomeric receptor signaling. Finally, the recently discovered ability of ligands to selectively activate non-G protein-mediated signaling through GPCRs may prove therapeutically relevant.
The concept of agonist selective trafficking of receptor signaling has received much attention as it prompts the search for drugs that can change the quality as well as the quantity of efficacy [26] . It is now clear that even the terms agonist and antagonist are strictly context-dependent. If a ligand can discriminate between multiple 'active' receptor conformations to preferentially activate a subset of effector pathways, then agonist efficacy needs to be defined in terms of the assay used to measure receptor activation. In the broadest sense, all ligands that productively engage a GPCR have the potential to be 'pluri-protean', acting as both agonist and antagonist depending on the signaling function measured and the nature of the cellular environment. In some cases it may be useful to re-classify compounds based on a full profile of stimulus-response coupling. Separating agonists in this manner could offer insights into preferred profiles of agonism as compounds progress from screening assays into therapeutically-oriented secondary assays. In situations where an original screening program was limited to measuring a single signaling pathway, consideration should be given to re-examining the properties of some compounds that were initially disregarded on the basis of apparently poor efficacy [170] . As ongoing work provides greater insights into the multitude of factors that give texture to GPCR signaling, the challenge will be to exploit the complex behavior of these receptors for therapeutic advantage while minimizing the pitfalls associated with too narrow a vision of receptor function.
CONCLUSIONS
For the majority of its experimental lifetime, information flow through GPCRs has been envisioned as unidirectional, i.e. changes in receptor conformation produced by agonist binding promote the transfer of information from outside the cell inwards. Recent experimentation, however, has demonstrated that receptor conformation is also controlled by protein-protein interactions occurring inside the cell. Receptor dimerization and interactions with scaffolding and signaling proteins can modify ligand selectivity and predetermine, from a menu of available options, which intracellular responses will predominate. In essence, the influences on receptor conformation are bi-directional; internal factors change the conformation of the receptor to reflect the status of the intracellular milieu, while extracellular factors, i.e. agonists, convey information to the cell about the external environment. This concept has critical implications for receptor theory and the design of therapeutics. Thus in complex physiological processes, e.g. aging or neurodegenerative disease, in which multiple protein expression patterns are changed it is more likely than previously thought that GPCR signal conditioning could be affected. Therefore if indeed there is an alteration of GPCR pharmacology in these states then perhaps drug design should be targeted toward this new pharmacology rather than the standard models previously used.
If one accepts the premise that the association of GPCRs with intracellular proteins places a constraint on the array of 'active' conformations that the receptor can adopt, then even within a single cell there may exist different 'flavors' of the same receptor, pre-wired to produce specific responses to preferred ligands. In the limit case of one neuron expressing multiple copies of the same receptor it seems unlikely that every copy of the receptor would be coupled to the same signal transduction machinery at all times. This is certainly Fig. (1) . Differential receptor complex pre-assembly allows efficient and rapid activation of multiple signal transduction pathways. In panel A we consider a single isoform of a heptaphelical GPCR. Upon ligand stimulation the receptor can activate multiple intracellular signal transduction pathways resulting in different responses, , , and . In this scenario the ligand interacts with a base inactive state receptor and then mediates promiscuous coupling with various downstream signaling factors to induce the multiple responses. In contrast however, in panel B we consider that the stable association of the base, inactive state of the receptor with various accessory proteins results in the generation of various stable forms of the receptor, i.e. the differently colored 'flavors'. The tertiary structure, isomerizational capacity (between active and inactive states), connection to downstream transduction pathways and eventual responses of each of the GPCR 'flavors' is a function of the coterie of accessory proteins that constitute it. Therefore the ligand can binds to differing 'flavors' of the receptors that are predisposed to activate certain signaling outcomes. If indeed the endogenous ligand may have multiple structural forms, or the receptor binds multiple endogenous ligands, it is conceivable that a ligand selection event may take place at the different receptor 'flavors'. Due to the different tertiary structures and isomerzational capacity imparted on the helical core by the accessory proteins, ligand selectivity may be induced into this receptor system so that certain ligands only induce specific signaling events. Thus with ligand selection occurring due to the differential receptor complex formation there is the generation of distinct intracellular signaling responses, despite the central receptor helical cores being identical in their primary sequence.
true if the receptor is susceptible to G protein 'switching' induced by heterologous desensitization [171] , or capable of signaling through -arrestins [86, 87] . These various receptor 'flavors' could preferentially interact with different ligands, e.g. CRLR-RAMP1 recognizing calcitonin generelated peptides and CRLR-RAMP2-RCP binding adrenomedullin [74, 75] , or activate different downstream effectors in response to the same ligand. We have recently invoked the latter scenario with respect to tissue-specific differences in GnRH receptor signaling [54] .
An interesting corollary of this postulate is that GPCRs may not be 'truly' promiscuous in the sense of a single receptor interacting with multiple effector pathways in a random manner. If GPCRs can be preassembled with their downstream transduction machinery, it may be biophysically more efficient to generate a variety of receptor 'flavors' that are hard-wired to specific transduction pathways than to switch a single receptor between different pathways (Fig. 1) . Such a model could accommodate experimentally observed promiscuity if the primary response pathway is defined as that mediated by the receptor 'flavor' with the highest affinity for a given agonist, whereas promiscuous coupling results from the activation of alternative receptor 'flavors' that have lower affinity for the ligand and therefore are only activated by higher agonist concentrations. Reversal of agonist efficacy could similarly result from altered ligand selectivity imposed from inside the cell through protein-protein interactions affecting ligand affinity. While selective examples of each of these phenomena exist, additional experimentation will be required to determine whether these mechanisms have broad applicability to models of GPCR signaling. 
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